中华流行病学杂志
中華流行病學雜誌
중화류행병학잡지
CHINESE JOURNAL OF EPIDEMIOLOGY
2012年
11期
1181-1183
,共3页
张焕虎%孙胜波%韩传吉%孙绍伟
張煥虎%孫勝波%韓傳吉%孫紹偉
장환호%손성파%한전길%손소위
肝细胞肝癌%门静脉癌栓%肝动脉插管化疗栓塞%门静脉化疗
肝細胞肝癌%門靜脈癌栓%肝動脈插管化療栓塞%門靜脈化療
간세포간암%문정맥암전%간동맥삽관화료전새%문정맥화료
Hepatic cell cancer%Portal vein tumor thrombus%Transcatheter arterial chemoembolization%Portal vein chemotherapy
目的 探讨双途径化疗[经DDS泵门静脉化疗(PVC)联合肝动脉插管化疗栓塞(TACE)]预防术后肝细胞肝癌和门静脉癌栓复发的临床疗效及安全性.方法 将2009年1月至2011年1月威海市立医院收治的87例有手术指征肝癌合并门静脉癌栓患者随机分成3组,切除肿瘤并取癌栓后A组行TACE、B组行经DDS泵PVC,C组行经DDS泵PVC联合TACE.随访3组患者术后6个月及1、2、3年无瘤生存率及累积生存率,并进行统计学分析.结果 术后6个月及1、2、3年无瘤生存率及累积生存率C组均高于A、B组.术后6个月、1年时差异无统计学意义(P＞0.05)；术后2、3年时差异有统计学意义(P＜0.01).上消化道出血的发生率C组与A、B两组间差异无统计学意义(P＞0.05).结论 肝细胞肝癌合并门静脉癌栓患者手术切除肿瘤并取癌栓后,行经DDS泵PVC联合TACE较单独PVC或TACE有效提高其远期无瘤生存率及累计生存率,且不增加上消化道出血的发生率.
目的 探討雙途徑化療[經DDS泵門靜脈化療(PVC)聯閤肝動脈插管化療栓塞(TACE)]預防術後肝細胞肝癌和門靜脈癌栓複髮的臨床療效及安全性.方法 將2009年1月至2011年1月威海市立醫院收治的87例有手術指徵肝癌閤併門靜脈癌栓患者隨機分成3組,切除腫瘤併取癌栓後A組行TACE、B組行經DDS泵PVC,C組行經DDS泵PVC聯閤TACE.隨訪3組患者術後6箇月及1、2、3年無瘤生存率及纍積生存率,併進行統計學分析.結果 術後6箇月及1、2、3年無瘤生存率及纍積生存率C組均高于A、B組.術後6箇月、1年時差異無統計學意義(P＞0.05)；術後2、3年時差異有統計學意義(P＜0.01).上消化道齣血的髮生率C組與A、B兩組間差異無統計學意義(P＞0.05).結論 肝細胞肝癌閤併門靜脈癌栓患者手術切除腫瘤併取癌栓後,行經DDS泵PVC聯閤TACE較單獨PVC或TACE有效提高其遠期無瘤生存率及纍計生存率,且不增加上消化道齣血的髮生率.
목적 탐토쌍도경화료[경DDS빙문정맥화료(PVC)연합간동맥삽관화료전새(TACE)]예방술후간세포간암화문정맥암전복발적림상료효급안전성.방법 장2009년1월지2011년1월위해시립의원수치적87례유수술지정간암합병문정맥암전환자수궤분성3조,절제종류병취암전후A조행TACE、B조행경DDS빙PVC,C조행경DDS빙PVC연합TACE.수방3조환자술후6개월급1、2、3년무류생존솔급루적생존솔,병진행통계학분석.결과 술후6개월급1、2、3년무류생존솔급루적생존솔C조균고우A、B조.술후6개월、1년시차이무통계학의의(P＞0.05)；술후2、3년시차이유통계학의의(P＜0.01).상소화도출혈적발생솔C조여A、B량조간차이무통계학의의(P＞0.05).결론 간세포간암합병문정맥암전환자수술절제종류병취암전후,행경DDS빙PVC연합TACE교단독PVC혹TACE유효제고기원기무류생존솔급루계생존솔,차불증가상소화도출혈적발생솔.
Objective To study the achievements and safety of Transcatheter arterial chemoembolization (TACE) associated Portal Vein Chemo-therapy (PVC) per-drug delivery system (DDS) program in preventing the recurrence of hepatic cell cancer (HCC) and Portal Vein Tumor Thrombus (PVTT).Methods 97 cases with HCC and PVTT were treated from Januay 2009 to January 2011.Patients with tumor or tumor thrombus were resected on all the cases and randomly divided into 3 groups.TACE,PVC per-DDS TACE and PVC per-DDS were given to group A,group B,and group C,respectively.Patients in the 3 groups were followed and compared on the Disease Free Survivals (DFS) and the accumulative survival rates,at 6 months,1 year and 2 years after the operation.Results After the surgery was completed in June,the 1-year,2-year,3-year survival rates and cummulative survival rate in group C was higher than in group A or group.Significant differences did no appeare in June but did show in 1 year after the surgery (P＞0.05) as well as in both 2 and 3 years,after the surgery (P＜0.01).Conclusion Patients with HCC and PVTT,the TACE chemotherapy in association with PVC per-DDS could increase both the DFSs and accumulative survival rates,when compared to the either single TACE or PVC per-DDS,after the tumor or tumor thrombus were resected.
